Immunome (IMNM) Share-based Compensation (2019 - 2026)

Immunome (IMNM) has 8 years of Share-based Compensation data on file, last reported at $8.0 million in Q1 2026.

• Quarterly Share-based Compensation rose 39.45% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.9 million (up 44.83% YoY) and the FY2025 annual result came in at $81.5 million, up 8.38% from the prior year.
• Share-based Compensation advanced to $8.0 million in Q1 2026, from $7.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.0 million in Q1 2026 to a low of $1.0 million in Q2 2023.
• A 5-year average of $3.5 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation dropped 22.16% — and 2024, when it soared 395.47%.
• Tracing IMNM's Share-based Compensation over 5 years: stood at $1.4 million in 2022, then fell by 18.52% to $1.1 million in 2023, then soared by 395.47% to $5.5 million in 2024, then soared by 44.3% to $7.9 million in 2025, then rose by 0.76% to $8.0 million in 2026.
• The last three Share-based Compensation figures came in at $8.0 million (Q1 2026), $7.9 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.